Matrixyl is the trade name for palmitoyl pentapeptide-4, a synthetic peptide built around a five amino-acid sequence: lysine-threonine-threonine-lysine-serine, or KTTKS. You will also see it written as pal-KTTKS, palmitoyl pentapeptide-3 (its older name), or by CAS number 214047-00-4. The French ingredient maker Sederma launched it as a cosmetic active around 2000.
The interesting part is where that KTTKS sequence comes from. It is a fragment of type I procollagen. When your body assembles collagen, the propeptide ends get cleaved off, and KTTKS is one of those released pieces.
What it is and how it's proposed to work
KTTKS belongs to a group called matrikines — short peptide fragments that act as signals to skin cells. In a 1993 paper in the Journal of Biological Chemistry, Katayama and colleagues identified KTTKS as a subfragment of the type I procollagen C-terminal propeptide and showed it stimulated extracellular matrix production by human dermal fibroblasts in culture. They reported dose-dependent increases in type I collagen, type III collagen, and fibronectin, without raising total protein synthesis. The working idea is that the released fragment acts as a feedback signal telling fibroblasts to keep building matrix.
KTTKS on its own does not pass through skin well. The "palmitoyl" part is a 16-carbon fatty acid attached to the peptide's N-terminus, added to make the molecule lipophilic enough to cross the skin's lipid barrier. That is the whole design rationale: take an active collagen-signalling fragment and bolt on a fatty tail so it can actually reach the dermis when applied topically.
What the research shows
The most-cited human trial is Robinson et al. (2005) in the International Journal of Cosmetic Science. It was a 12-week, double-blind, placebo-controlled, split-face study in 93 women aged 35–55. One side of the face got a moisturiser containing 3 ppm pal-KTTKS, the other got the same moisturiser without it. The peptide side showed significant improvement over placebo for fine lines and wrinkles by both instrumental image analysis and expert grading, and it was well tolerated. Note the framing: this is a topical cosmetic study measuring wrinkle appearance, not a drug trial.
There is also lab work on the fatted version directly. A separate study looked at the collagen-stimulating effect of the C16-KTTKS amphiphile on human fibroblasts, consistent with the matrikine signalling story.
A few honest caveats. Much of the foundational data is in-vitro or comes from cosmetic-industry research. Effective concentrations in the headline trial are very low (3 ppm, i.e. 0.0003% of the active), and topical results describe changes in skin appearance rather than verified deep structural remodelling. Marketing claims that put precise wrinkle-reduction percentages on it tend to outrun what the peer-reviewed trials actually measured.
Regulatory and quality notes
Palmitoyl pentapeptide-4 has been used and studied as a cosmetic ingredient, applied to the skin. It is not an approved drug, and nothing here is medical, dosing, or efficacy advice. Anything sold as raw peptide for non-cosmetic use should be treated as research-use-only and not for human consumption.
If you are buying a raw peptide rather than a finished cream, identity and purity are the things that matter, because "palmitoyl pentapeptide-4" on a label tells you nothing about what is in the vial. A third-party certificate of analysis showing identity (mass spec) and purity (HPLC) for the specific lot is the relevant check. peptideone aggregates independent vendor quality signals and published COAs rather than testing anything itself.